Soquelitinib for Eczema

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Recruiting

Sponsor: Corvus Pharmaceuticals, Inc.

Must not be taking: Immunosuppressants, Corticosteroids, JAK inhibitors

Disqualifiers: Psoriasis, Skin infections, Pregnancy, others

Trial Summary

What is the purpose of this trial?

This trial is testing a new drug called Soquelitinib to help people with severe skin problems. It targets those with moderate to severe Atopic Dermatitis and works by blocking a protein that causes inflammation.

Will I have to stop taking my current medications?

Yes, you may need to stop certain medications. The trial requires that you have not taken oral prednisone or similar drugs within 2 weeks before starting, and other immunosuppressive medications within 4 weeks before starting.

Eligibility Criteria

Adults over 18 with moderate to severe atopic dermatitis (eczema) who haven't had success with certain topical or systemic therapies can join. Participants must use contraception and women of childbearing potential must follow specific contraceptive guidance.

Inclusion Criteria

I am 18 years old or older.

My skin condition has been confirmed as atopic dermatitis by a dermatologist.

My skin condition is moderate to severe, covering more than 10% of my body.

See 3 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive soquelitinib or placebo tablets orally at specified dose levels for 28 days

4 weeks

Daily administration

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 weeks

Treatment Details

Interventions

Soquelitinib (Janus Kinase Inhibitor)

Trial OverviewThe trial is testing the safety, tolerability, and initial effectiveness of a drug called Soquelitinib compared to a placebo in adults with moderate to severe atopic dermatitis.

Participant Groups

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Soquelitinib Dose EscalationExperimental Treatment1 Intervention

Participants will receive soquelitinib tablets orally at one of four dose levels (100 mg twice daily, 200 mg once daily, 200 mg twice daily, 400 mg once daily) for 28 days

Group II: PlaceboPlacebo Group1 Intervention

Participants will receive placebo tablets orally once daily or twice daily for 28 days